Breast cancer patients’ experiences on endocrine therapy: monitoring with a checklist for patients on endocrine therapy (C-PET)

Malinovszky, K. M.; Cameron, David; Douglas, Sheena; Love, C.D.B.; Leonard, Tom; Dixon, J. Michael; Hopwood, Penelope; Leonard, Robert

doi:10.1016/j.breast.2004.02.009

Cited by 26 publications

(18 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, a few studies have reported some changes in body weight (especially weight gains) in women with resected breast cancer receiving adjuvant treatment including tamoxifen (Camoriano et al, 1990;Chlebowski et al, 2002;Malinovszky et al, 2004).…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, they have often reported a range of events attributed to tamoxifen therapy, including weight gain (Hoskin et al, 1992;Rose et al, 1993). A checklist-based study of patients on endocrine therapy found that weight gain was a common problem in patients on tamoxifen (Malinovszky et al, 2004), but the results of large-scale, randomised clinical trials such as NSABP-B14 and NSABP-P1 suggest that adjuvant tamoxifen therapy is not associated with an increased risk of weight gain, although it must be pointed out that they considered only body weight and not body composition (Fisher et al, 1989(Fisher et al, , 1998. Nevertheless, adult weight gain is largely reflected in increased body fat, which may be more suitable for assessing adiposity and its metabolic consequences than body weight or the body mass index (BMI), which reflect both lean and fat body mass (Abu-Abid et al, 2002).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids

et al. 2006

View full text Add to dashboard Cite

Recent studies have shown that administering the aromatase inhibitor exemestane after 2 -3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment. Although many of the adverse effects associated with exemestane and tamoxifen have been analysed, there are no comparative data concerning body weight and body composition. The aim of this randomised study was to evaluate the longitudinal changes in body composition and lipid profiles in postmenopausal women switched from tamoxifen to exemestane. In total, 60 overweight or obese postmenopausal patients were enrolled. Their anthropometric data, body composition, including fat mass (FM) and fat-free mass (FFM), and lipid profiles, caloric intake and physical activity were assessed 1 week before randomisation, and 6 and 12 months later. In all, 55 patients (27 on tamoxifen and 28 on exemestane) completed the 1-year study period. Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group; the between-group difference was statistically significant (Po0.01). The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group; the between-group difference was statistically significant (Po0.05). Triglycerides and high-density lipoprotein cholesterol significantly decreased (Po0.01; Po0.05), and low-density lipoprotein cholesterol significantly increased (Po0.01) in the exemestane group at the end of the 1-year study period. Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids

et al. 2006

View full text Add to dashboard Cite

show abstract

“…One study of women on tamoxifen reported weight gain in 61 % of premenopausal as compared to 39 % of postmenopausal women (p = 0.000) [62]. Another study reported that weight gain in breast cancer patients was significantly greater in women on tamoxifen as compared to no tamoxifen (p \ 0.05)-especially in premenopausal (p \ 0.01) as compared to postmenopausal women (p \ 0.05) [50].…”

Section: Risk Factors For Weight Gainmentioning

confidence: 95%

“…The third study also reported differing rates of weight gain on tamoxifen for premenopausal (61 %) versus postmenopausal women (39 %) (p = 0.000) [46].…”

Section: Tamoxifen and Aimentioning

confidence: 96%

“…Three studies reporting weight gain in women on tamoxifen compared to AIs reported widely varying results within unclear time frames: weight gain in 14 % on tamoxifen versus 15 % AI (mix of AIs) [44], 31 % tamoxifen versus 33 % AI (unspecified AIs) [45], and 43 % tamoxifen versus 30 % anastrozole [46]. The third study also reported differing rates of weight gain on tamoxifen for premenopausal (61 %) versus postmenopausal women (39 %) (p = 0.000) [46].…”

Section: Tamoxifen and Aimentioning

confidence: 99%

See 1 more Smart Citation

Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence?

Nyrop

Muss

et al. 2016

Breast Cancer Res Treat

View full text Add to dashboard Cite

Most breast cancer (BC) tumors are early stage and hormone receptor positive, where treatment generally includes adjuvant endocrine treatment (ET). Oncology providers and women about to start ET want to know about side effects, including potential weight gain. The aim of this study was a literature review to identify the independent effect of ET on post-diagnosis weight gain. Weight gain is of concern with regard to potential associations with BC recurrence, mortality, and quality of life in survivorship. We conducted a targeted review of the literature. Thirty-eight studies met our inclusion criteria. Patient-reported weight gain ranged widely from 18 to 52 % of patients in Year 1 and from 7 to 55 % in Year 5. Some studies reported categories of weight change: lost weight (9-17 %), stable weight (47-64 %), and gained weight (27-36 %). Most studies comparing ET with placebo or tamoxifen with AI reported no significant difference between the two groups. Wide-ranging and inconsistent results point to the need for further research to clarify annual weight change (loss, gain, stability) from BC diagnosis through 5 years of ET and beyond. There is also a need to explore weight change by type of ET and to explore risk factors for weight gain in women on ET, including tumor type, sociodemographic characteristics, and health behaviors. More specific information is needed to identify high-risk BC patients who could be targeted for weight management interventions.

show abstract

The use of questionnaires for measuring patient‐reported side effects of drugs: its importance and methodological challenges

Foster

Molen

Caeser³

et al. 2008

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

Patient-reported outcomes such as Quality of Life often play an important part in the efficacy assessment of drug treatment. Although instruments that measure quality of life can detect the positive effects of treatments on health status, they may not measure the effect of negative treatment-related symptoms. Patients often fail to spontaneously report common or clinically mild drug-related symptoms, even though the same symptoms can result in the stopping or skipping of prescribed doses. Therefore, as with quality of life assessments, the perception of patients on possible side effects of treatments is best captured by the use of self-report questionnaires. There are substantial challenges with creating well-validated, relevant questionnaires that capture the full range of patient-reported symptoms and signs. A review of 13 existing instruments showed that many patient-rated side effect questionnaires had been developed, often to a high standard, using well-established psychometric methods. However, there were some inconsistencies in the methods used by the questionnaire developers, indicating the need for standardisation when creating new, or adapting previous, instruments. Even with their current deficits, it is important that patient-reported side effect questionnaires be used more in drug development, health outcomes research and resource allocation; all with the ultimate aim of improving quality of patient care.

show abstract

Breast cancer patients’ experiences on endocrine therapy: monitoring with a checklist for patients on endocrine therapy (C-PET)

Cited by 26 publications

References 11 publications

Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids

Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids

Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence?

The use of questionnaires for measuring patient‐reported side effects of drugs: its importance and methodological challenges

Contact Info

Product

Resources

About